Volume | 537,584 |
|
|||||
News | - | ||||||
Day High | 9.86 | Low High |
|||||
Day Low | 9.36 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Astria Therapeutics Inc | ATXS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
9.50 | 9.36 | 9.86 | 9.55 | 9.35 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
7,434 | 537,584 | $ 9.50 | $ 5,106,424 | - | 4.26 - 16.90 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:01:44 | priorref | 331 | $ 9.55 | USD |
Astria Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
468.87M | 54.90M | - | 0 | -72.89M | -1.33 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Astria Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATXS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.18 | 9.86 | 8.97 | 9.32 | 1,187,786 | 0.37 | 4.03% |
1 Month | 11.55 | 11.73 | 8.77 | 10.05 | 908,805 | -2.00 | -17.32% |
3 Months | 15.37 | 16.90 | 8.77 | 13.20 | 1,055,693 | -5.82 | -37.87% |
6 Months | 4.99 | 16.90 | 4.26 | 11.26 | 833,778 | 4.56 | 91.38% |
1 Year | 13.00 | 16.90 | 4.26 | 10.74 | 520,397 | -3.45 | -26.54% |
3 Years | 8.53 | 16.90 | 2.36 | 10.43 | 272,235 | 1.02 | 11.96% |
5 Years | 8.53 | 16.90 | 2.36 | 10.43 | 272,235 | 1.02 | 11.96% |
Astria Therapeutics Description
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. |